Journal
ROYAL SOCIETY OPEN SCIENCE
Volume 9, Issue 4, Pages -Publisher
ROYAL SOC
DOI: 10.1098/rsos.211991
Keywords
PD-1; PD-L1; nanoparticles; immunotherapy; cancer treatment; combination therapy
Categories
Ask authors/readers for more resources
Nanomedicine has potential in oncology field, but only a few products have been approved. Immunotherapy, as a new direction in cancer treatment, still requires further development. Using PD-1/PD-L1-targeting nanocarriers can enhance treatment outcomes.
Although nanomedicines have been in the oncology field for almost three decades with the introduction of doxil, only a few nanomedicine products have reached approval. Can nanotechnology be a realistic tool to reduce the number of hospital beds? At present, several clinically approved anti-PD-1/PD-L1 antibodies or CAR T cell-based therapies are available; however, the immunotherapy field is far from mature. Will immunotherapy be the fourth pillar of cancer treatment? In this review, we summarized the current status of immunotherapy using PD-1/PD-L1-targeting nanocarriers. The knowledge on material science, therapeutic agents and formulation designs could pave the way for high-efficacy treatment outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available